 IRVINE, Calif., Oct. 18, 2021 GLOBE NEWSWIRE -- Inari Medical, Inc. NASDAQ: NARI Inari a medical device company focused on developing products to treat and transform the lives of patients suffering from venous diseases, announced planned enrollment of the PEERLESS trial. PEERLESS is a new randomized controlled trial RCT comparing the clinical outcomes of patients with intermediate-high risk pulmonary embolism PE treated with the FlowTriever System versus catheter-directed thrombolysis CDT. The trial design was presented at the 7th Annual Pulmonary Embolism Symposium, sponsored by the PERT Consortium. 